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background:  Early phase studies of novel interventions for hypertension, such as renal sympathetic denervation, are sometimes single-
armed (uncontrolled). We explored the wisdom of this by quantifying the blood pressure fall in the placebo arms of contemporary trials of 
hypertension.
Methods:  We searched Medline up to June 2014 and identified blinded, randomised trials of hypertension therapy in which the control 
arm received placebo medication or a sham (placebo) procedure. For non-resistant hypertension, we identified all such trials of drugs 
licensed by the US Food and Drug Administration (FDA) since 2000 (five drugs). This FDA-related restriction was not applied to resistant 
hypertension trials.
Results:  This produced 7451 patients who were allocated to a blinded control from 52 trials of non-resistant hypertension, and 694 
patients from 8 trials of resistant hypertension (three drugs and two interventions). Systolic blood pressure fell by 5.92mmHg (95% CI: 
5.14-6.71; p<0.00001) in the non-resistant cohort and by 8.76 mmHg (95% CI: 4.83-12.70; p<0.0001) in the resistant cohort. Using meta-
regression, the falls were larger in trials that did not use ambulatory blood pressure monitoring as an inclusion criterion (z=2.84, p=0.0045) 
and those where the patients were prescribed a continuous background of anti-hypertensives (z=-2.72, p=0.0065).
conclusion:  The non-trivial magnitude of these apparent blood pressure reductions with perfectly ineffective intervention (placebo) 
illustrates that efficacy explorations of novel therapies for hypertension, once safety is established, should be performed with a randomised, 
appropriately controlled and blinded design.
